This is a Phase 3 Randomized Double-Blind Placebo-Controlled 1-year Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Obstructive Sleep Apnea.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
660
Change from Baseline in Apnea-Hypopnea Index (AHI)
AHI, Apnea-Hypopnea Index, is the number of apneas or hypopneas recorded via polysomnography during the study per hour of sleep. Apnea is defined as a cessation of airflow lasting at least 10 seconds, hypopnea as a decrease in airflow by at least 30% from baseline for at least 10 seconds occurring with a drop in oxygen saturation (SpO2) by at least 4%.
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Sleep Disorders Center of Alabama
Birmingham, Alabama, United States
Chandler Clinical Trials
Chandler, Arizona, United States
Preferred Research Partners, Inc.
Little Rock, Arkansas, United States
Orange County Research Institute
Anaheim, California, United States
Marvel Clinical Research, LLC
Huntington Beach, California, United States
CenExel CNS
Los Alamitos, California, United States
Santa Monica Clinical Trials
Los Angeles, California, United States
Empire Clinical Research
Pomona, California, United States
Pacific Research Network
San Diego, California, United States
SDS Clinical Trials Inc.
Santa Ana, California, United States
...and 54 more locations